Bleeding News and Research

RSS

UC researcher receives funding to study bone complications in people with sickle cell disease

September is National Sickle Cell Awareness Month, and a University of Cincinnati College of Medicine hematology researcher has received new grant funding to study one of the disease's painful, under-recognized complications: bone damage.

25 Sep 2026

Stroke rates nearly doubled among younger adults over three decades

Stroke is becoming more common among younger adults, according to a study published September 23, 2026, in Neurology, the medical journal of the American Academy of Neurology.

23 Sep 2026

Study identifies B cells as drivers of immunotherapy-related colitis

Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown role for B cells, which are adaptive immune cells, in triggering and sustaining colitis occurring as a side effect of immune checkpoint inhibitors, a widely used form of cancer immunotherapy.

22 Sep 2026

Simple test could take the pain out of womb cancer check

A new test to identify cells collected from urine and vaginal fluid could help rule out womb and other cancers in most women who experience bleeding after the menopause, find University of Manchester researchers.

22 Sep 2026

EVITA clinical trial evaluates oral vitamin C for pre-cancerous blood disorders

Vitamin C boosts the activity of cellular proteins called TET enzymes that help control which genes are turned on or off.

21 Sep 2026

Mifepristone offers effective emergency contraception with fewer side effects

Emergency contraception containing mifepristone prevents more pregnancies with fewer side effects than some other common emergency contraceptive pills such as levonorgestrel, according to a new Cochrane review involving 87 trials.

20 Sep 2026

B cells may play a role in triggering immunotherapy-related colitis

18 Sep 2026

Big Picture Bio founded to identify, design and optimize promising cancer combination therapies

Big Picture Bio Ltd., has been founded to identify, design and optimize promising cancer combination therapies, using a generative world model to understand how tumors, immune cells and surrounding tissue interact across disease sites and patient subgroups.

From Big Picture Bio 18 Sep 2026

New clinical guidelines standardize kidney replacement therapy in ICU patients

Acute kidney injury (AKI) is a common and severe complication in the intensive care unit (ICU). Due to its high incidence, strong correlation with poor prognosis, and substantial consumption of medical resources, AKI has become one of the central challenges in modern critical care medicine.

17 Sep 2026

Siemens Healthineers brings new CN-3000 and CN-6000 hemostasis testing systems to US labs to help manage growing workloads

Siemens Healthineers announced today that the automated hemostasis analyzers for mid- and high-volume laboratories are now available for patient testing in the United States.

From Siemens Healthineers 17 Sep 2026

Peer-reviewed study shows six times lower blood damage in Realheart® TAH than market-leading device in vitro

Scandinavian Real Heart AB (publ) announces today that a study sponsored by the company has been published in the peer-reviewed journal Nature Scientific Reports, showing that the Realheart® TAH causes about six times less blood damage (hemolysis) than the only FDA-approved artificial heart device currently in wide clinical use.

16 Sep 2026

Newly diagnosed AML patients benefit from less-intensive combination treatment

Investigators from the Mass General Brigham Cancer Institute have found that adults with newly diagnosed acute myeloid leukemia (AML) receiving a less-intensive combination of azacitidine and venetoclax had more than twice as much time before treatment failed, the leukemia returned or worsened, or they died, compared with patients receiving intensive chemotherapy.

2 Sep 2026

Study reveals why many patients fail to recover after stroke

A clot forms. Blood flow to the brain is blocked. Starved of oxygen, neurons begin to die.

2 Sep 2026

Catheter-directed thrombolysis improves short-term outcomes in pulmonary embolism patients

In patients with intermediate−high risk pulmonary embolism, catheter-directed thrombolysis improved short-term clinical outcomes compared with standard anticoagulation therapy alone, according to results presented in a Hot Line session today at ESC Congress 2026.

31 Aug 2026

Anticoagulation lowers subclinical leaflet thrombosis after TAVI procedure

After transcatheter aortic valve implantation (TAVI), anticoagulation reduced imaging signs of clot formation on the new valve compared with antiplatelet therapy, without compromising safety. This was the main finding of the ACASA-TAVI trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in JAMA.

31 Aug 2026

TAVI-first strategy proves noninferior to PCI-first approach in new trial

A TAVI-first strategy was noninferior to a PCI-first strategy after one years' follow-up, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

30 Aug 2026

Functional angiography outperforms conventional imaging in AIR-STEMI trial

Functional coronary angiography significantly reduced cardiovascular events and improved safety compared with conventional angiography in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.

29 Aug 2026

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Trial shows antiplatelet therapy needs personalization after stent implantation

Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had undergone stent implantation 12 months earlier.

29 Aug 2026

Milvexian fails to reduce cardiovascular events after acute coronary syndrome

Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was no increase in intracranial or fatal bleeding.

29 Aug 2026